Universal Oral Vaccine for Influenza Infections
- Author:
Yap Wei BOON
1
;
Toong Seng TAN
;
Sharifah Syed HASSAN
Author Information
1. Jeffrey Cheah School of Medicine and Health Sciences Monash University Malaysia Jalan Lagoon Selatan Bandar Sunway, 47500 Subang Jaya Selangor, Darul Ehsan Malaysia
- Publication Type:Original article
- Keywords:
Influenza viruses;
NS1;
oral vaccines;
probiotic;
lactobacillus
- From:Malaysian Journal of Health Sciences
2018;16(2):51-64
- CountryMalaysia
- Language:English
-
Abstract:
Each year, influenza A infections have caused tremendous death rate as high as 300,000-500,000 globally. Althoughthere are effective anti-influenza agents and vaccines, high mutational rate among influenza A viruses renders dramaticdecline in the effectiveness of anti-influenza agents or vaccines in certain individuals. The situation is further complicatedby limitations in influenza vaccine production, for instance, long production period, limited vaccine capacity and lackof cross-protection against various influenza A virus strains. To solve these issues, development of universal influenzavaccine based on conserved antigens such as non-stuctural protein 1 (NS1) has been endeavoured. NS1 protein is highlyconserved in all influenza A virus strains known by far, produced abundantly on infected cell surfaces and responsible formaintaining virulence. Furthermore, cytotoxic T-lymphocytes that are active against NS1 were also reported to be ableto avoid shedding of influenza in hosts. To better inhibit influenza infections, oral immunization has long been proposeddue to feasibility of this method to be implemented and safer for recipients while able to target influenza A viruses fromthe entry point. Lactobacillus has been vastly studied for its roles as bacterial carrier in oral vaccine development dueto its significant probiotic properties. For examples, stimulation of immune responses in oral and airway mucosal layers,high colonization in oral and airway mucosal layers and great natural adjuvant effects. In this light, influenza universaloral vaccine developed using NS1 dan Lactobacillus should be further studied in influenza oral vaccine design.
